With weight loss drugs such as Ozempic and Mounjaro seemingly able to melt the pounds away, you might well think you'll never need a 'diet plan' again. Alas, you'd be wrong. As a leading weight ...

Tirzepatide, the active ingredient in Eli Lilly's diabetes drug Mounjaro, may be an effective alternative to painful daily treatment for a rare disorder, according to research published Jan. 29 in ...

The shortage, which began in December 2022 for Mounjaro and extended to Zepbound in April 2023, led to a surge in demand for compounded versions of the drugs. But with tirzepatide removed from the ...

Eli Lilly's weight-loss jab Mounjaro has been cleared for rollout by the NHS in England, with around 3.4 million people eligible, but will be made available in stages to limit the financial impact.

Demand for weight loss jabs continues to surge, particularly as the NHS began offering Wegovy in late 2023 and will start offering Mounjaro to patients in March 2025. They have also become ...

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight ...

Manufactured by Eli Lilly and Company, both Mounjaro and Zepbound contain the active ingredient tirzepatide. Tirzepatide is similar to semaglutide, which is used in medications like Ozempic, Rybelsus, ...